European Commission Grants Marketing Authorization for Eisai's Zonegran for epilepsy

Main Category: Epilepsy
Article Date: 21 Mar 2005 - 0:00 PDT

Current ratings for:
'European Commission Grants Marketing Authorization for Eisai's Zonegran for epilepsy'

Patient / Public:not yet rated

Healthcare Prof:not yet rated


Tokyo (JCNN) - Eisai announced on March 16 that its UK subsidiary Eisai Ltd. has received marketing authorization for Zonegran from the European Commission (EC) as of March 10.

This authorization allows the product to be marketed in EU countries for the adjunctive treatment for partial seizures of adult epilepsy patients.

Developed by Eisai, the zonisamide agent Zonegran is currently marketed in the US and Japan (trade name Excegran). By adding the product to its line of nerve drugs, the company aims to meet patients' needs and increase its presence in the EU.

View Eisai Co., Ltd. company profile here

Copyright © 2001-2004 JCNN. All rights reserved. A division of Japan Corporate News Network KK.

View drug information on Zonegran.


Article adapted by Medical News Today from original press release.
Visit our epilepsy section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Angela Lower. "European Commission Grants Marketing Authorization for Eisai's Zonegran for epilepsy." Medical News Today. MediLexicon, Intl., 21 Mar. 2005. Web.
26 May. 2012. <http://www.medicalnewstoday.com/releases/21570.php>
APA
Angela Lower. (2005, March 21). "European Commission Grants Marketing Authorization for Eisai's Zonegran for epilepsy." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/21570.php.

Please note: If no author information is provided, the source is cited instead.


Add Your Opinion On This Article

'European Commission Grants Marketing Authorization for Eisai's Zonegran for epilepsy'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Your Name:*
E-mail Address:*
Your Opinion Title:*
Opinion:*
This is to help prevent SPAM submissions. Please enter the words exactly as they appear, including capital letters and punctuation.*

* Fields marked with a * need to be filled in before you hit the submit button.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.


Epilepsy

Most Popular Articles



Follow Our Epilepsy News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Epilepsy Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »